Bicara Therapeutics (BCAX) announced the first patients have been enrolled in FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in combination with pembrolizumab in first line recurrent/metastatic head and neck squamous cell carcinoma. Ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor directed monoclonal antibody with a domain that binds to human transforming growth factor beta.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.